Disc Medicine's rejected sun-sensitivity drug clears Phase 3, reopening FDA path

Overview

Updated 2 hours ago

People with erythropoietic protoporphyria feel stabbing pain in any strong light; sunlight literally hurts. Disc Medicine's oral pill bitopertin just aced a Phase 3 trial, giving the company a second shot at FDA approval after a rejection in February.

The drug cut protoporphyrin IX by 46% (placebo: 4%) and added 12.2 pain-free hours in light. Disc plans to resubmit its application by year-end, with an FDA decision as early as mid-2027; shares jumped 35% on the news.

Why it matters

If the FDA approves bitopertin next year, sunlight-sensitive EPP patients get the first oral option to tolerate light without the Scenesse implant.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

46%

PPIX reduction at six months vs 4% placebo

Whole-blood metal-free protoporphyrin IX, the toxic compound behind EPP pain, fell sharply on bitopertin.

12.2 hours

Added pain-free time in light vs placebo

Improvement in cumulative time patients could stay in light without pain during treatment month six.

35%

Share jump on Oct 19, 2026

Disc's best trading day since 2022 after the Phase 3 announcement.

$1.7B

Projected peak sales for bitopertin

BMO Capital Markets estimate, anticipating early uptake among patients already on expanded access.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

People Involved

John Quisel

Chief executive, Disc Medicine

Leading the bitopertin resubmission

Vinay Prasad

Former director, FDA Center for Biologics Evaluation and Research

Left FDA after leadership change

Organizations Involved

Disc Medicine

Clinical-stage biopharmaceutical company

Planning FDA resubmission for bitopertin

Disc Medicine licensed bitopertin from Roche and is repurposing it for erythropoietic protoporphyria; bitopertin would be its first approved product.

Roche / Genentech

Multinational pharmaceutical company

Licensor of bitopertin

Roche developed bitopertin for schizophrenia, abandoned it after trial failures, and licensed it to Disc Medicine.

Clinuvel Pharmaceuticals

Specialty pharmaceutical company

Markets the only approved EPP therapy

Clinuvel markets Scenesse, an implant that increases skin melanin to shield EPP patients from light.

LEO Pharma

Pharmaceutical company

Developing dersimelagon as a competing oral EPP drug

LEO Pharma is developing dersimelagon, another oral EPP candidate that could win FDA approval next year.

Timeline

October 2025 October 2026

4 events Latest: Yesterday

Tap a bar to jump to that date

October 2026
Phase 3 APOLLO hits all endpoints
Latest Clinical trial

Bitopertin cuts PPIX 46% vs 4% placebo and adds 12.2 pain-free hours in light; stock jumps 35%, Disc launches a $350M offering.
Yesterday
June 2026
FDA agrees APOLLO can support resubmission
Regulatory

Disc reaches a meeting agreement that the ongoing Phase 3 trial measuring clinical outcomes could back a full approval filing.
June 2026
February 2026
FDA rejects accelerated approval
Regulatory

A complete response letter says trials don't clearly link PPIX reduction to sunlight tolerance, and asks for a Phase 3 clinical-outcomes study.
February 2026
October 2025
FDA grants rare priority review voucher
Regulatory

Bitopertin becomes one of the first drugs to receive a commissioner's national priority voucher, cutting review timelines to 1-2 months.
October 2025

Scenarios

FDA clears bitopertin by mid-2027, giving EPP its first oral therapy

Likely Resolves by Q3 2027

Discussed by: BMO Capital Markets, Disc Medicine leadership

The FDA completes a standard priority review of the resubmitted application and approves bitopertin. Analysts expect early uptake from patients already in expanded access; BMO projects peak sales of $1.7 billion. Approval would mark Disc's first marketed drug and the first oral treatment for EPP.

FDA issues a second complete response letter, delaying launch to 2028

Possible Resolves by Q3 2027

Discussed by: FDA's prior scrutiny of the PPIX-to-benefit link

Reviewers find a gap in the resubmission, asking for longer safety data or another trial. Any launch slips past mid-2027, extending Disc's cash-burn and reliance on the public offering.

Dersimelagon reaches the market first and splits the oral EPP field

Possible Resolves by End of 2027

Discussed by: LEO Pharma, market analysts

LEO Pharma wins FDA approval for its oral EPP candidate dersimelagon around 2027, giving both oral options and pressuring bitopertin's launch share and pricing.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

March 1998

Sildenafil (Viagra) repurposing (1998)

Pfizer developed sildenafil to treat hypertension and angina. Clinical trials failed, but patients reported a side effect that led Pfizer to reposition it for erectile dysfunction. The FDA approved it in 1998 with first-year sales near a billion dollars.

Then

Sildenafil became a blockbuster within a year.

Now

It became the textbook example of repurposing a failed drug, reshaping how pharma scans abandoned compounds.

Why this matters now

Bitopertin is another repurposed failure, dropped by Roche after schizophrenia trials. One positive Phase 3 in a new disease is turning a discarded molecule into a potential approval.

June 2021 – January 2024

Aduhelm (Biogen) surrogate-endpoint approval (2021-2024)

The FDA approved Biogen's Alzheimer's drug on amyloid reduction despite an advisory committee's opposition. Medicare refused broad coverage, and Biogen withdrew the drug in 2024.

Then

Aduhelm sold poorly amid coverage limits and criticism.

Now

The case hardened scrutiny of surrogate endpoints, making regulators demand proof that biomarkers translate into patient benefit.

Why this matters now

The same question sank Disc's first bid: does lowering PPIX actually reduce pain? The APOLLO trial was designed to answer that clinical question directly.

February 2011 – March 2023

Makena confirmatory-trial reversal (2011-2023)

The FDA approved Makena via accelerated approval on a surrogate for preventing preterm birth. A 2019 confirmatory trial failed, and the FDA moved to withdraw the drug.

Then

Makena was formally removed from the market in 2023.

Now

It became the clearest example of accelerated approval unraveling when confirmatory data contradict the surrogate.

Why this matters now

APOLLO is Disc's attempt to avoid the Makena path. By measuring pain-free light exposure rather than only a biomarker, it aims to confirm what the February rejection said was missing.